BPC-157 10MG Common Reconstitution Reference Vial size: 10 mg Common educational reference: Add 3.0 mL bacteriostatic water Final concentration: ~3.33 mg/mL 1 unit on U-100 syringe: ~33.3 mcg Common educational reference range: 200600 mcg daily with gradual titration That same style of protocol math is commonly shown in third-party educational references for BPC-157 10MG
View Study [3]"Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior" Graf MV, Kastin AJ, 1984 Finding: In healthy volunteers, DSIP increased total sleep time by 59% during the day and improved subsequent night sleep quality
People are probably getting a little dizzy with these acronyms, but I think we're doing a good job of guiding people along
Researched applications In the published preclinical and clinical literature the effects of Cagrilintide are documented in the following areas: Obesity (stand-alone) , Phase 2 data (Lau 2021, 10.8 % at 4.5 mg) Obesity + Semaglutide (CagriSema) , Phase 3 REDEFINE 1 (25.3 %) T2DM + obesity , Phase 3 REDEFINE 2 Cardiovascular prevention , Phase 3 REDEFINE 3 (n ~ 7000) MASLD/MASH , exploratory in Phase 2 Type 2 diabetes (monotherapy) , preclinical data Prediabetes , exploratory plans Science & studies 4.1 Key publications Lau D.C.W., Erichsen L., Francisco A.M., et al
The dosing used in successful bone healing studies typically ranged from 0.01 mg/kg to 0.01 mg/kg body weight
Saline is fine for many single-peptide reconstitutions but it is the wrong solvent for any vial containing a copper peptide